Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database by Wenchao Lu, Shihan Wang, Huilin Tang, Tao Yuan, Wei Zuo, Yuling Liu

Subjects: Get full text

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus by Xu He, Xu He, Xu He, Wei Zhao, Wei Zhao, PeiHang Li, PeiHang Li, YinJiang Zhang, YinJiang Zhang, GuoHua Li, HongYu Su, BiNan Lu, BiNan Lu, ZongRan Pang, ZongRan Pang

Subjects: Get full text

Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential by Tohada M. AL-Noshokaty, Rehab Abdelhamid, Nourhan M. Abdelmaksoud, Aya Khaled, Mariam Hossam, Razan Ahmed, Toka Saber, Shahd Khaled, Shereen Saeid Elshaer, Ahmed I. Abulsoud

Subjects: Get full text

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity by Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser

Subjects: “…GLP-1RAs…”
Get full text

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review by Yao Wang, Jiangling Wang, Qian Gong, Haoming Wu, Shuhao Yang, Jufeng He, Xulin Hu, Tianfang Huang

Subjects: “…glucagon-like peptide-1 receptor agonists (glp-1ras)…”
Get full text